ST Nuotai (688076.SH) 2025 Annual Profit Distribution: Cash Dividend of RMB 0.35 per Share

Gelonghui, June 4 — ST Nuotai (688076.SH) announced its 2025 annual profit distribution implementation notice. The dividend distribution is based on the company's total share capital of 316,051,897 shares prior to the implementation of the plan, with a cash dividend of RMB 0.35 per share (tax inclusive), amounting to a total cash dividend of RMB 110,618,163.95. The record date for this equity distribution is June 11, 2026, and the ex-dividend date is June 12, 2026.

Gelonghui FinanceJun 4 17:09

Express News | Nuotai Bio: Sulindac and Bifonazole Active Pharmaceutical Ingredients Pass GMP Compliance Inspection

BreakingsMay 28 09:02

ST Notai (688076.SH): The company's self-developed Class 2.2 new drug, Semaglutide Injection, has not applied for priority review.

Gelonghui reported on May 12 that ST Notai (688076.SH) stated on the investor interaction platform that the company's self-developed Class 2.2 new drug, Semaglutide Injection, has not applied for priority review.

Gelonghui FinanceMay 12 16:48

ST Nuotai reported revenue of 19.43 billion yuan in 2025, an increase of 19.57%, and net profit of 3.32 billion yuan, a decrease of 17.80%.

In 2025, the company's revenue reached RMB 1.943 billion (+19.57%), but net profit attributable to parent company shareholders was RMB 332 million (-17.80%). The main reasons were a 5.06 percentage point decline in gross margin, a 213.50% surge in financial expenses, an administrative penalty of RMB 47.4 million, and increased asset impairment. The revenue structure continued to improve, with self-selected products accounting for 70.42% and overseas income contributing 70.27%. Both R&D investment and selling expenses increased, while cash flow improved significantly.

lanjinger.comApr 30 15:03

ST Nuotai: ST Nuotai: 2025 Annual Report

SZSIApr 30 00:00 · Announcements

ST Nuotai: ST Nuotai: First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements